Mandate

Vinge advises Biotage in connection with its acquisition of Astrea from KKR’s life science platform Gamma

Vinge advises Biotage AB (publ) (“Biotage”) in connection with its acquisition of Astrea Bioseparations (“Astrea”), a high-growth chromatography solutions provider from Gamma Biosciences (“Gamma”), a life sciences tools platform created and controlled by KKR.

The acquisition extends Biotage’s chromatography franchise into the higher-growth and larger bioprocessing segment, while also increasing exposure to biologics and advanced therapeutic customers.

The purchase price will be paid in new ordinary shares in Biotage, entailing that the KKR-controlled Gamma is expected to become the largest shareholder in Biotage, with an ownership of approximately 17 percent.

The transaction is subject to shareholder approval by the general meeting of Biotage and customary closing conditions, including approvals from the UK authorities.

Vinge’s team consisted of Matthias Pannier, Karl Klackenberg, Linus Adolfsson, Sebastian Saadieh, Elis Allmark (M&A), Dain Hård Nevonen, William Kåge, Joel Magnusson, Anna Svensson, Gabriel Chabo (Capital Markets), Sebastian Örndahl (Anti-trust), Sara Dahlros Sköld and Julia Hagelberg (VDR).

Related

Vinge is advising on the establishment of Ballista Capital

Ballista Capital held its final closing on 9 June 2025. The investor base primarily comprises family offices and investors with strong ties to northern Sweden.
July 07, 2025

Vinge advises The Qt Company Ltd on its public offer for I.A.R. Systems Group AB (publ)

The Qt Company Ltd (“The Qt Company”), a wholly owned subsidiary of Qt Group Plc, has announced a public tender offer to the shareholders of I.A.R. Systems Group AB (publ) (“IAR”) to tender all class B shares in IAR to The Qt Company at a price of SEK 180 in cash per share
July 04, 2025

Vinge has advised Consolid on the establishment of Consolid Equity III

The fund held its final closing on June 2, 2025, having secured commitments from a diverse investor base that includes several leading institutional investors from Europe and North America, as well as established fund-of-funds. The fundraising was highly successful, with the fund significantly oversubscribed. Consolid Equity III has more than doubled its total commitments compared to its predecessor fund.
July 02, 2025